MorphoSys, Merck Serono to develop new therapeutic antibodies
As part of the deal, MorphoSys and Merck’s biopharmaceutical division Merck Serono, will join forces to develop therapies that modulate the immune system’s natural ability to combat tumors.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.